Key result
Rosiglitazone treatment for 3 weeks in Zucker diabetic fatty rats restored endothelium-dependent vasorelaxation but did not improve the mechanical properties or remodeling of the femoral artery.
Why the study?
Does rosiglitazone improve endothelial dysfunction and mechanical remodeling of femoral arteries in Zucker diabetic fatty rats?
Does rosiglitazone improve endothelial dysfunction and mechanical remodeling of femoral arteries in Zucker diabetic fatty rats?
p-value: p=<0.05
In a diabetic rat model, short-term rosiglitazone treatment reverses endothelial dysfunction but fails to improve vascular mechanical remodeling.
Indicates endothelial selectivity of rosiglitazone in diabetic rats; leaves open translation to human vascular remodeling.
OBJECTIVES: Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of treatment with rosiglitazone (Rosi) on endothelial function and mechanical remodeling. METHODS: The Rosi treatment was given to ZDF rats for 3 weeks. The endothelium-dependent vasodilation and alpha-adrenoceptor-dependent vasoconstriction of femoral arteries were studied using an ex-vivo isovolumic myograph. The biomechanical passive property of the arteries was studied in Ca2+-free condition. The expressions of endothelial nitric oxide synthase (eNOS), alpha-adrenoceptor, matrix metalloproteinase 9 (MMP9), and elastase were evaluated. RESULTS: Endothelium-dependent vasorelaxation of the femoral artery was blunted at low doses in ZDF rats at 11 weeks of age and attenuated at all doses in ZDF rats at 19 weeks of age. The expression of eNOS was consistent with the endothelium-dependent vasorelaxation. The alpha-adrenoceptor was activated and the mechanical elastic modulus was increased in ZDF rats at 19 weeks of age. The expressions of alpha-adrenoceptor, MMP9, and elastase were up regulated in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks restored endothelium-dependent vasorelaxation and the expression of eNOS and the adrenoceptor activation at the doses below 10-6 mole/L in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks did not, however, improve the mechanical properties of blood vessel, the expressions of alpha-adrenoceptor, MMP9, and elastase in ZDF rats. CONCLUSION: The endothelial dysfunction and mechanical remodeling are observed as early as 19 weeks of age in ZDF rat. Rosi treatment for 3 weeks improves endothelial function but not mechanical properties.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2010) studied Type 2 diabetes (animal model) (n=37). Rosiglitazone vs. Vehicle was evaluated on Endothelium-dependent vasorelaxation and mechanical properties of the femoral artery (p=<0.05). Rosiglitazone treatment for 3 weeks in Zucker diabetic fatty rats restored endothelium-dependent vasorelaxation but did not improve the mechanical properties or remodeling of the femoral artery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: